Press ReleasesPress ReleasesQuarterly ResultsIsoray Announces the Appointment of Donna Fort as Vice President Sales and MarketingApril 13, 2021University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical ResectionMarch 31, 2021Isoray to Present at the Oppenheimer 31st Annual Healthcare ConferenceMarch 3, 2021Isoray Announces the Appointment of Lisa Lauer As Vice President Business DevelopmentFebruary 16, 2021Isoray Announces Second Quarter Fiscal 2021 Financial ResultsFebruary 9, 2021Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021February 5, 2021Isoray Announces Pricing of $45 Million Public OfferingFebruary 4, 2021Isoray Announces Proposed Underwritten Public OfferingFebruary 3, 2021Isoray to Present at the H.C. Wainwright BioConnect 2021 ConferenceJanuary 7, 2021Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRONovember 24, 2020Isoray Announces First Quarter Fiscal 2021 Financial ResultsNovember 10, 2020Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020November 2, 20204 12345678 5
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical ResectionMarch 31, 2021
Isoray Announces the Appointment of Lisa Lauer As Vice President Business DevelopmentFebruary 16, 2021
